Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY-0102 Monotherapy in Advanced Solid Tumors
NCT06094777Phase 1Recruiting
- Sponsor
- Yingli Pharma
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HY-0102 in solid tumor, urothelial carcinoma (UC), colorectal cancer (CRC) and 1 more, sponsored by Yingli Pharma. Primary endpoints: Occurrence of drug limiting toxicities at 28 days, Incidence of Treatment-emergent adverse events and serious adverse events and 3 more. Started Dec 2023; status: recruiting.
02
Drugs
HY-0102
03
Conditions
solid tumorurothelial carcinoma (UC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06094777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094777.